SLDB Solid Biosciences Inc
Price (delayed)
$7.54
Market cap
$291.01M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.3
Enterprise value
$220.45M
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by
Highlights
The EPS rose by 47% year-on-year and by 16% since the previous quarter
The debt fell by 8% YoY and by 2% QoQ
SLDB's quick ratio is up by 27% year-on-year but it is down by 11% since the previous quarter
The equity is up by 18% year-on-year but it has declined by 8% since the previous quarter
Key stats
What are the main financial stats of SLDB
Market
Valuations
Earnings
Shares outstanding
38.6M
Market cap
$291.01M
Enterprise value
$220.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.5
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$90.51M
EBITDA
-$86.9M
Free cash flow
-$86.29M
Per share
Balance sheet
Liquidity
EPS
-$3.3
Free cash flow per share
-$2.11
Book value per share
$5.04
Revenue per share
$0
TBVPS
$5.64
Total assets
$230.98M
Total liabilities
$37.74M
Debt
$25.3M
Equity
$193.25M
Working capital
$182.92M
Debt to equity
0.13
Current ratio
13.45
Quick ratio
12.95
Net debt/EBITDA
0.81
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-43.7%
Return on equity
-53.8%
Return on invested capital
-67.8%
Return on capital employed
-41.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLDB stock price
How has the Solid Biosciences stock price performed over time
Intraday
-4.92%
1 week
-8.5%
1 month
-14.99%
1 year
141.67%
YTD
22.8%
QTD
32.98%
Financial performance
How have Solid Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$100.03M
Net income
-$90.69M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 13% year-on-year
Growth
What is Solid Biosciences's growth rate over time
Valuation
What is Solid Biosciences stock price valuation
P/E
N/A
P/B
1.5
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 47% year-on-year and by 16% since the previous quarter
The price to book (P/B) is 31% more than the last 4 quarters average of 1.2 but 8% less than the 5-year quarterly average of 1.7
The equity is up by 18% year-on-year but it has declined by 8% since the previous quarter
Efficiency
How efficient is Solid Biosciences business performance
The ROIC is up by 16% YoY and by 3.8% QoQ
The return on assets has declined by 6% year-on-year but it rose by 2.9% since the previous quarter
Solid Biosciences's return on equity has decreased by 4.7% YoY but it has increased by 3.8% QoQ
Dividends
What is SLDB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLDB.
Financial health
How did Solid Biosciences financials performed over time
SLDB's quick ratio is up by 27% year-on-year but it is down by 11% since the previous quarter
Solid Biosciences's current ratio has increased by 27% YoY but it has decreased by 10% QoQ
The debt is 87% lower than the equity
The debt to equity has contracted by 24% YoY but it has grown by 8% from the previous quarter
The equity is up by 18% year-on-year but it has declined by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.